All In Biotech

Drug Trial Radar · NCT07709637

Evaluation of Safety, Tolerance, and Efficacy of Allogeneic LB-DTK-COV19 in Severe Coronavirus Disease 2019 Patients

A Single Center, Open-Label, Phase I Study to Evaluate the Safety, Tolerance, and Efficacy of Allogeneic LB-DTK-COV19 Cells in Severe Coronavirus Disease 2019 Patients

Last checked: Nov 20, 2026Latest source record: Aug 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

1

Actual

Start

Jul 31, 2025

Primary completion

Oct 31, 2026

Study completion Oct 31, 2026

Sponsor

Lead sponsor
LucasBioIndustry
Sponsor type
Industry
First posted
Jul 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the safety, tolerability, and efficacy of allogeneic SARS-CoV-2-Specific T cells (LB-DTK-COV19) in patients with persistent clinical symptoms following a positive SARS-CoV-2 PCR test for 14 days or longer. The main questions it aims to answer are: * What is the maximum tolerated dose of LB-DTK-COV19 based on dose-limiting toxicity? * What treatment emergent adverse events occur following LB-DTK-COV19 infusion? * Does LB-DTK-COV19 result in clinically significant improvement or worsening of clinical symptoms following infusion? Participants will: * Receive a single intravenous infusion of LB-DTK-COV19 (low dose: 5x10\^6/m\^2; mid dose:1x10\^7/m\^2; high dose: 2x10\^7/m\^2). * Attend follow-up visits at the clinic for 6 months after the infusion.

Conditions

  • COVID-19
  • COVID-19 (SARS-CoV-2 Infection)

Interventions

  • LB-DTK-COV19Biological

    LB-DTK-COV19 is an allogeneic SARS-CoV-2-specific T cell therapy product derived from third-party donors and is stored frozen in a colorless, transparent freeze-dried vial until thawed into liquid before administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. NCI-CTCAE v5.0 ≥ Grade 3 RateTime frame: From baseline visit through 24 weeks after treatment initiation.
  2. Adverse EventsTime frame: From the baseline visit through 24 weeks after treatment initiation.
  3. Disease Progression RateTime frame: From the screening visit through 24 weeks after treatment initiation.
  4. WHO Ordinal ScaleTime frame: From the screening visit through 24 weeks after treatment initiation.
  5. NEWS2 ScoreTime frame: From the screening visit through 24 weeks after treatment initiation.
  6. Viral loadTime frame: From the screening visit through 24 weeks after treatment initiation.
  7. SARS-CoV2-Specific T-cell ResponsesTime frame: From the screening visit through 24 weeks after treatment initiation.
  8. Characterization of SARS-CoV-2-Specific T cellsTime frame: From the screening visit through 24 weeks after treatment initiation.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Catholic University of Korea Seoul St.Mary's Hospital

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.